We have examined the biochemical and histological effects of high concentrations of dopamine (0.05-1.0 ,umol) injected into the rat striatum. Twenty-four hours after such injections, the oxidation products of dopamine and dihydroxyphenylacetic acid were detected as both free and protein-bound cysteinyl dopamine and cysteinyl dihydroxyphenylacetic acid. Protein-bound cysteinyl catechols were increased 7-to 20-fold above control tissue levels. By 7 days postinjection, the protein-bound cysteinyl catechols were still detectable, although reduced in concentration, whereas the free forms could no longer be measured. Histological examination of striatum at 7 days revealed a central core of nonspecific damage including neuronal loss and gliosis. This core was surrounded by a region containing a marked reduction in tyrosine hydroxylase immunoreactivity but no apparent loss of serotonin or synaptophysin immunoreactivity. When dopamine was injected with an equimolar concentration of either ascorbic acid or glutathione, the formation of protein-bound cysteinyl catechols was greatly reduced. Moreover, the specific loss of tyrosine hydroxylase immunoreactivity associated with dopamine injections was no longer detectable, although the nonspecific changes in cytoarchitecture were still apparent. Thus, following its oxidation, dopamine in high concentrations binds to protein in the striatum, an event that is correlated with the specific loss of dopaminergic terminals. We suggest that the selective degeneration of dopamine neurons in Parkinson's disease may be caused by an imbalance between the oxidation of dopamine and the availability of antioxidant defenses.
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We have examined the biochemical and histological effects of high concentrations of dopamine (0.05-1.0 ,umol) injected into the rat striatum. Twenty-four hours after such injections, the oxidation products of dopamine and dihydroxyphenylacetic acid were detected as both free and protein-bound cysteinyl dopamine and cysteinyl dihydroxyphenylacetic acid. Protein-bound cysteinyl catechols were increased 7-to 20-fold above control tissue levels. By 7 days postinjection, the protein-bound cysteinyl catechols were still detectable, although reduced in concentration, whereas the free forms could no longer be measured. Histological examination of striatum at 7 days revealed a central core of nonspecific damage including neuronal loss and gliosis. This core was surrounded by a region containing a marked reduction in tyrosine hydroxylase immunoreactivity but no apparent loss of serotonin or synaptophysin immunoreactivity. When dopamine was injected with an equimolar concentration of either ascorbic acid or glutathione, the formation of protein-bound cysteinyl catechols was greatly reduced. Moreover, the specific loss of tyrosine hydroxylase immunoreactivity associated with dopamine injections was no longer detectable, although the nonspecific changes in cytoarchitecture were still apparent. Thus, following its oxidation, dopamine in high concentrations binds to protein in the striatum, an event that is correlated with the specific loss of dopaminergic terminals. We suggest that the selective degeneration of dopamine neurons in Parkinson's disease may be caused by an imbalance between the oxidation of dopamine and the availability of antioxidant defenses.
The neuropathological hallmark of Parkinson's disease is the selective degeneration of dopamine (DA) neurons in the nigrostriatal projection. In the majority of cases, the cause of this selective neurodegenerative process is not known. However, accumulating evidence suggests that endogenous DA may act as a neurotoxin and thereby participate in the pathophysiology of the disease. For example, DA appears to be involved in the striatal neuropathology associated with several conditions, including ischemia (1, 2) , exposure of the area to high levels of excitatory amino acids (3, 4), and systemic methamphetamine treatment (5, 6) . Evidence for the involvement of DA in this neuropathology derives from the observation that, in each case, toxicity was attenuated by pharmacologically or surgically reducing striatal DA availability prior to the insult. DA, 3,4-dihydroxyphenylalanine (dopa), and other catechols also have been shown to be toxic when applied directly to cells in culture (7, 8) .
The mechanism underlying DA-induced toxicity is thought to involve the inherent instability of the catechol moiety of the molecule. Like the neurotoxin 6-hydroxydopamine, DA readily oxidizes to form reactive oxygen species, free radicals,
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. and quinones, a process that can occur either spontaneously in the presence of transition metal ions (9) or via an enzymecatalyzed reaction (10). Free radicals can damage cellular components such as lipids, proteins, and DNA (11). Likewise, the electron-deficient quinones also react readily with cellular nucleophiles (12, 13) and this, too, can lead to cytotoxicity.
Reduced sulfhydryl groups in the form of free cysteine, glutathione (GSH), or cysteinyl residues on proteins are the strongest nucleophiles within the cell. Conjugates of GSH or free cysteine with the catechol-derived quinones have been isolated as free cysteinyl-catechols in DA-rich brain regions of several species and are thought to reflect in vivo DA oxidation (14). The amount of free cysteinyl-catechols has been shown to increase under conditions presumed to promote oxidation, such as reserpine treatment (15), ascorbic acid deficiency (16), and aging (17).
In addition to the free cysteinyl catechols, the oxidation products of DA and its deaminated metabolite dihydroxyphenylacetic acid (DOPAC) also have been shown to bind covalently to cysteinyl residues on striatal protein in vitro (13). Since cysteinyl residues often are located at the active site of a protein, covalent modification by a catechol-derived quinone could result in an impairment of protein function with potentially deleterious effects on the cell. Indeed, we have hypothesized that binding of the catechol-derived quinone to critical proteins within the cell is responsible at least in part for the toxicity associated with exposure to high concentrations of DA (13).
The present study was conducted to determine whether the DA oxidation that we have observed in striatal slices in vitro can also occur in vivo and, if so, whether it is accompanied by neurotoxicity. We report that intrastriatal injections of DA resulted in covalent binding of catechols to cysteinyl residues on protein and that this was correlated with selective and nonselective forms of cytotoxicity. 80% and 20% of the total acid-soluble supernatant were frozen and stored at -70°C until utilized for the analyses of free cysteinyl catechols and parent catechols, respectively. The protein pellet was washed by resuspension and recentrifugation in the homogenizing solution and then subjected to acid hydrolysis as described (13). In all samples, the catechol moieties were extracted with alumina and then either the parent catechols or their cysteinyl catechol derivatives were analyzed by HPLC with electrochemical detection (13). The HPLC system utilized in these studies was as described (13) TH immunoreactivity served as a marker for dopaminergic terminals in striatum, serotonin immunoreactivity was used to visualize serotonergic terminals, and synaptophysin immunoreactivity was used as a nonspecific marker for the variety of terminals present in this structure. Sections processed for immunocytochemistry were incubated for 40 hr at 4°C in phosphate-buffered saline (pH 7.4) containing 0.3% Triton X-100, 0.5 mg of bovine serum albumin per ml, and antibody. Mouse anti-rat TH antibody (diluted 1:20,000; Chemicon), mouse anti-rat synaptophysin antibody (diluted 1:1000; Sigma), or rabbit anti-rat serotonin (diluted 1:8000; Incstar, Stillwater, MN) was used, the specificity of each having been previously demonstrated (19) (20) (21) (22) . Sections were then processed by the avidin-biotin method (23) using the Standard Vectastain kit (Vector Laboratories) and diaminobenzidine. For each antibody, all sections from each animal in a given experiment were processed together. For each animal every fifth section was processed for TH, and the immediately adjacent sections were stained for Nissl substance with thionine. These sections were used to identify the location of the injection site and the extent of the histological damage. In subsequent experiments, sections located between TH-labeled sections showing evidence of histological damage were processed with the other antibodies. Following the completion of these procedures, sections were mounted on slides, and the diaminobenzidine reaction product was intensified as described (24). Sections were then dehydrated, coverslips were placed using Permount, and the slides were coded as to experimental condition.
METHODS AND MATERIALS
Two approaches were used to quantify the size of the damaged area in the striatum for each injection. First, the coded TH-labeled sections were screened to identify the three sections (from a one in five series of consecutive 40-,um sections) with the largest cross-sectional area of diminished TH immunoreactivity. The cross-sectional area of TH loss was then quantified on each of these sections by tracing the perimeter of this region using a computer-assisted image analysis system (Southern Micro Instruments, Atlanta). The area and diameter of this region were then calculated, and the section with the largest area of loss was used for comparisons across animals. Similar measures of the extent of tissue damage and gliosis were made on the adjacent Nissl-stained section. Second, to assess the reliability of this measure of lesion size, the sections through the most rostral and caudal portions of the lesioned area were also identified, and the distance between them (number of sections x 40 ,um) was determined. This distance, a measure of the diameter of the lesioned area, was then compared with the diameter of the lesioned area determined from the single section with the largest cross-sectional area. The significant (P < 0.0001) positive correlation between these two measures (r = 0.940; n = 16 animals) indicated that the cross-sectional area determinations provided a reliable measure of lesion size.
Statistical Analyses. Differences among group means were assessed with one-way ANOVA. When the ANOVA reached statistical significance (P < 0.05), Scheffe's method (a level -0.05) was used for between-group comparisons. cysteinyl catechols were present at levels -20-fold above free cysteinyl catechol levels in the DA injected group (Table 1) . Protein-bound cysteinyl catechols still were above control levels 7 days following the injection (Table 1) , although free cysteinyl catechols were not detectable at that time. Tissue DA levels were reduced by 32% at both 24 hr and 7 days (Table 1) . However, tissue DOPAC levels were unchanged (at 24 hr) or elevated 26% above control (at 7 days), resulting in a DOPAC/DA ratio that was 136% and 179% of control at 24 hr and 7 days, respectively. The amount of DA oxidation at 24 hr as determined by proteinbound cysteinyl catechols significantly increased with increasing amounts of exogenous DA (Fig. 1A) . Histological Evidence of Toxicity. Seven days after an intrastriatal injection of DA (0.4 ,umol), the area surrounding the injection site exhibited neuronal loss and marked gliosis ( Fig. 2A) . This region of nonspecific damage was surrounded by a zone of damage specific to DA terminals as demonstrated by the loss of TH immunoreactivity (Fig. 2B) , with the preservation of normal striatal cytoarchitecture as viewed with a Nissl stain. In addition, synaptophysin immunoreactivity appeared to be unchanged in this zone of decreased TH labeling, and serotonin immunoreactivity may actually have been increased (Fig. 3) . The size of the zone of damage to DA axons, as determined by the cross-sectional area of diminished TH immunoreactivity, significantly increased with increasing amounts of exogenous DA (Fig. 1B) postinjection. The addition of cantioxidants significantly reduced the aimouillt of protein-bound cysteinyl catechols associlatd with an injectioni of DA ((1.4 fLmol) bv 50 -6()0% cornpared to DA injected without antioxidants (Fig. 4) . Similar results were obtalined when equimolar antioxid'ants were coilljected with a higher concentration of DA (1.0 p.mol). The impact of antioxidants on the amount of histological danmage associated w ith 'an injection of DA was evalu-ated at 7 days (Fig. 2) . The injection of DA ((1.4 jimol) with an equimolar concentrationi of GSH or ascorbate resulted in Ca greatly reduced areal of histological damage compared to that caused bv DA alone. When DA was administered with either antioxidant. Nissl staiin revealed a central region of nonspecific darmage as had bcc scen in striatal tissue injected wvith DA alone (Fig. '2. C. arnd E). However. uinder these conditions the surrounding zone of decreased TH immunoreactiv itv that had been obsersed with injections of DA -alone was no longer present ( Fig. 2 B. D, and F) . Quantification of the lesion area based on the absence TH immunoreactivitv showed that a'ntioxidants reduced the totalI lesion area by 70% campared to the effects of DA alone (Fig. 5) . Analysis of the lesion area based on Nissl stain alone. howsever. showved no reduction in the size ot the region of nonspecific damage caused bv the combninbation of DA and of antioxidCants (Fig. 5) .
RESULTS

DISCUSSION
Exposure of striatal tissue to hiogh concentrations of DA resulted 24 hr later in the formation of free and protein-bound cvstemnvl catechols. indicaiting that (a large anmount of DA and DOPAC had oxidized to the reactive quinone intermediates.
The protein-bound cvsteinyl catechols were present at levels 2(1-fold higher thaln the free cvsteinvl ccatechol derivatives. suggestinT tha1t the bound forms are an more sensitive measure are already working closer to the limits of their capacity to detoxify cellular oxidants than are other cells. This could be due, at least in part, to the necessity to maintain high concentrations of endogenous DA in the reduced state, as well as to remove the hydrogen peroxide generated during the normal metabolism of DA. There also is evidence to suggest that the extracellular antioxidants, mainly ascorbate, are maintained by the cells at the expense of their own intracellular stores (26). If so, then the consumption of extracellular ascorbate during the oxidation of DA in and around the synaptic space may result in the depletion of intracellular antioxidants, leading to an oxidative stress on the dopaminergic terminals.
The susceptibility of dopaminergic neurons to oxidant stress may contribute to the onset and progression of Parkinson's disease. Such a stress could result from an increase in the availability of DA within or surrounding the existing DA neurons or a decrease in the antioxidant capacity to maintain DA in the reduced state. On the one hand, localized areas of increased DA availability are suggested by increased synthesis and release of DA in residual DA terminals after partial degeneration of nigrostriatal neurons (27, 28 ). An increase in DA also occurs during treatment with L-dopa (29). On the other hand, there is evidence to suggest that conditions characterized by a decreased antioxidant capacity exist in brains of patients with Parkinson disease. Postmortem studies of the substantia nigra of Parkinsonian brain have shown decreased GSH (30), decreased GSH peroxidase (31), increased iron levels (32), and indices of lipid peroxidation (33). Finally, increased DA oxidation is indicated by an increased free cysteinyl DA/DA ratio with increasing depigmentation in human substantia nigra (34) and the observation that those neurons containing greater amounts of neuromelanin, a polymerization product of oxidized DA, are most susceptible to degeneration in Parkinson disease (35, 36).
As noted above, the effects of DA that we have described were seen in response to very large amounts of DA (0.05-1.0 Amol) injected in a small volume (2 ,ll) . Even at the lowest dose, this constitutes more DA than exists in the entire brain. Nonetheless, there are several reasons for believing that our observations are of potential relevance to a pathophysiological state. First, the concentration of DA in the region showing specific damage is undoubtedly well below that which occurs initially at the point of injection. Second, we are delivering DA over a period of 20 min, yet the neurodegenerative disease we are trying to understand probably develops over decades. Third, although we are injecting DA into otherwise healthy animals, we assume that many of those individuals who develop parkinsonism begin with a metabolic abnormality that reduces their ability to handle the reactive compounds formed from DA.
In conclusion, these findings indicate that in high concentrations, DA oxidizes to form products that bind to protein and that these or related reactive species are selectively toxic to dopaminergic neurons. We hypothesize that an imbalance between the rate of DA oxidation and inactivation of the reactive metabolites of DA can be contributing to the pathogenesis associated with Parkinson's disease.
